Protara Therapeutics (TARA) Net Income towards Common Stockholders (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$28.9 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 58.4% year-over-year to -$28.9 million in Q1 2026; TTM through Mar 2026 was -$88.8 million, a 52.32% decrease from a year earlier, with the FY2025 full-year figure at -$148.1 million, down 25.13% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$28.9 million, down from -$19.5 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for TARA reached as high as $10.8 million in Q1 2022 and fell as low as -$39.0 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$15.8 million across 5 years, with a median of -$17.7 million in 2024.
• Across the five-year window, Net Income towards Common Stockholders jumped 178.25% in 2022 and tumbled 270.9% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$39.0 million in 2022, then jumped by 73.77% to -$10.2 million in 2023, then dropped by 11.32% to -$11.4 million in 2024, then tumbled by 71.29% to -$19.5 million in 2025, then slumped by 48.42% to -$28.9 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$28.9 million in Q1 2026, -$19.5 million in Q4 2025, and -$19.4 million in Q3 2025.